Inactive Instrument

Press Releases Mylan N.V. Nasdaq

Stocks

MYL

NL0011031208

Pharmaceuticals

Press Releases

May. 18	U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain	PR
May. 07	Viatris to Present at the Bank of America Securities 2026 Healthcare Conference	PR
May. 07	Viatris : VTRS Q1 2026 Non-GAAP Reconciliations - FINAL	PU
May. 07	Viatris : VTRS Q1 2026 Earnings Presentation - FINAL	PU
May. 07	Viatris : VTRS Q1 2026 Earnings Infographic - FINAL	PU
May. 07	Viatris: Q1 Earnings Snapshot	AQ
May. 07	Viatris Reports First-Quarter 2026 Financial Results	PR
May. 05	Viatris Announces Quarterly Dividend	PR
May. 04	Viatris Announces Chief Financial Officer Transition	PR
May. 01	Viatris Announces Several Data Presentations on Investigational Low-Dose Estrogen Combined Hormonal Contraceptive Weekly Patch at the 2026 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting	PR
Apr. 13	Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting	AQ
Apr. 13	Viatris to Report First Quarter 2026 Financial Results on May 7, 2026	PR
Apr. 10	Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting	PR
Mar. 23	Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)	PR
Mar. 19	Viatris : VTRS Investor Event Presentation FINAL (1)	PU
Mar. 19	Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030	PR
Feb. 26	FDA Accepts Viatris Supplemental New Drug Application for MR-141 for the Treatment of Presbyopia	AQ
Feb. 26	Viatris : VTRS Q4 2025 Earnings Presentation FINAL	PU
Feb. 26	Viatris : VTRS Q4 2025 Non GAAP Reconciliations FINAL	PU
Feb. 26	Viatris : VTRS Q4 2025 Earnings Infographic	PU
Feb. 26	Viatris: Q4 Earnings Snapshot	AQ
Feb. 26	Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results	PR
Feb. 26	Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend	PR
Feb. 25	FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia	PR
Feb. 03	Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026	PR